The UK and US have reached a key trade agreement that will keep no levies on UK medicine exports going into the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to raise expenditure on pharmaceuticals through the NHS. This pledge secures that duties on these crucial exports will stay at zero for a duration of 36 months.
This development is in response to earlier threats to significantly raise import taxes on patented drug products, with potential rates mentioned up to double the cost.
"This arrangement with the Britain bolsters the worldwide climate for innovative medicines and establishes long-overdue equity to American-British drug exports," an announcement said.
Economic Importance
Drugs constitute one of the the United Kingdom's biggest export categories to the America, which is clearly the largest buyer for major British pharmaceutical firms.
Trade data reveal that in the one-year period leading up to the third quarter, the UK exported drugs worth billions to the US. This figure accounted for nearly one-fifth of total UK exports in that period.
"This deal secures work, stimulates capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," a government official commented.
Specific NHS Changes
The pact involves several notable commitments from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to double overall health service expenditure on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to stay within budget will be restricted at fifteen percent. Last year, rebates topped 20%.
Broader Context
This agreement follows a ongoing dispute between the sector and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by arguments that US patients were charged a premium for the same drugs than consumers in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS had to increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its total funding over the past decade.
